Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma

The document describes a study on the effects of BAY 43-9006, an oral kinase inhibitor, on patients with renal cell carcinoma. In a Phase I study, the recommended dose was established at 400 mg twice daily. Out of 41 patients in the Phase II trial, 30% had stable disease, 40% experienced a reduction in tumor size by more than 25%, and 30% had disease progression. Side effects were manageable and included hypertension, edema, diarrhea, hand and foot syndrome, rash, and hair loss when the rash affected the scalp. The Phase III trial was initiated for patients whose disease progressed after immunotherapy, and combination studies with other treatments were being considered. The study involved 116 patients and indicated that BAY 43-9006 prolonged time to disease progression but did not significantly improve overall survival. The drug's mechanisms may involve inhibition of PDGFR and potentially VEGFR2 and VEGFR3, although BRAF mutations found in melanoma were not present in renal cell carcinoma. Further research is needed to understand the drug's action and improve patient treatment selection.